Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHN-012
- Development stage
- Phase 1
- Lead developer
- Pheon Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PHN-012 is a **novel antibody-drug conjugate (ADC)** currently in first-in-human Phase I clinical trials. It is designed for the treatment of advanced solid tumors, including colorectal, non-small cell lung, and pancreatic cancers. The drug targets a **novel, undisclosed antigen** that is highly overexpressed in tumors. The mechanism of action is the delivery of a cytotoxic payload to tumor cells via a specific monoclonal antibody, leading to tumor cell death. PHN-012 is administered intravenously and is being evaluated for safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics, and pharmacodynamics. The developer is Pheon Therapeutics[1][5][6][7][9].
- Brand names
- PHN-012PHN012PHN 012
- Other names
- PHN-012PHN012PHN 012
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on PHN-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PHN-012.